<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0016-3813</journal-id>
<journal-title><![CDATA[Gaceta médica de México]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. Méd. Méx]]></abbrev-journal-title>
<issn>0016-3813</issn>
<publisher>
<publisher-name><![CDATA[Academia Nacional de Medicina de México A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0016-38132022000700001</article-id>
<article-id pub-id-type="doi">10.24875/gmm.m21000596</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Documento de consenso sobre el uso de los iSGLT2 en el tratamiento de pacientes con diabetes mellitus tipo 2]]></article-title>
<article-title xml:lang="en"><![CDATA[Consensus on the use of iSGLT2 in the treatment of patients with type 2 diabetes mellitus]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garnica-Cuéllar]]></surname>
<given-names><![CDATA[Juan C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lavalle-González]]></surname>
<given-names><![CDATA[Fernando J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Magaña-Serrano]]></surname>
<given-names><![CDATA[José A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Almeda-Valdés]]></surname>
<given-names><![CDATA[Paloma]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cetina-Canto]]></surname>
<given-names><![CDATA[José A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chávez Iñíguez]]></surname>
<given-names><![CDATA[Jonathan S.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garza-García]]></surname>
<given-names><![CDATA[Carlos A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Chávez]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Gálvez G]]></surname>
<given-names><![CDATA[Guillermo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medina-Chávez]]></surname>
<given-names><![CDATA[Juan H.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pimentel-Morales]]></surname>
<given-names><![CDATA[Gela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Pedraza]]></surname>
<given-names><![CDATA[Valentín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Centro Médico Nacional 20 de noviembre ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Autónoma de Nuevo León Hospital Universitario Dr. José E. Gonzále Clínica de Diabetes HU]]></institution>
<addr-line><![CDATA[Monterrey N.L]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional Siglo XXI Hospital de Cardiología]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Unidad de Investigación de Enfermedades Metabólicas Departamento de Endocrinología y Metabolismo]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Hospital Regional Departamento de Medicina Interna y Endocrinología]]></institution>
<addr-line><![CDATA[Mérida Yucactán]]></addr-line>
<country>México</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Hospital Civil de Guadalajara Fray Antonio Alcalde Departamento de Nefrología ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>México</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Clínica RENALL MTY Departamento de Nefrología ]]></institution>
<addr-line><![CDATA[Monterrey N.L]]></addr-line>
<country>México</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Hospital General de México Dr Eduardo Liceaga Clínica para la Atención Integral del Paciente con Diabetes y Obesidad ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Hospital Civil de Guadalajara Dr. Juan I. Menchaca Servicio de Endocrinología ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>México</country>
</aff>
<aff id="A10">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Coordinación Técnica de Excelencia Departamento de Medicina Interna y Geriatría]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="A11">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional Siclo XXI Hospital de Cardiología]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="A12">
<institution><![CDATA[,Hospital General de México Dr. Eduardo Liceaga Servicio de Endocrinología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<volume>158</volume>
<numero>spe</numero>
<fpage>1</fpage>
<lpage>14</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0016-38132022000700001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0016-38132022000700001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0016-38132022000700001&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Aunque en los últimos años en México ha mejorado la calidad de la atención de la diabetes mellitus (DM) y ha aumentado el acceso a servicios de salud y medicamentos, existe una falta de apego a las recomendaciones de las guías de práctica clínica, que podría explicar la falta de un control glucémico adecuado en muchos de los pacientes con DM. Los inhibidores del cotransportador de sodio-glucosa tipo 2 (iSGLT2) han sido la última clase de agentes antidiabéticos en recibir la aprobación de la Food and Drug Administration (FDA) y de la Comisión Federal para la Protección contra Riesgos Sanitarios de México (COFEPRIS). Con el fin de mejorar el uso de los iSGLT2 en la práctica clínica en México, en este documento se presentan las recomendaciones emitidas por un panel de 11 expertos mexicanos con base en las nuevas evidencias publicadas para el tratamiento de los pacientes con DM2.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Although in recent years in Mexico the quality of diabetes mellitus (DM) care has improved and access to health services and medications has increased, there is a lack of adherence to the recommendations of the clinical guidelines, which could explain the poor glycemic control in many of the patients with DM. Sodium-glucose cotransporter type 2 (iSGLT2) inhibitors have been the last class of antidiabetic agents to receive approval from the Food and Drug Administration (FDA) and COFEPRIS (Mexico). In order to improve the use of SGLT2i in clinical practice in Mexico, this paper presents the recommendations issued by a panel of eleven Mexican experts based on the new published evidence for the treatment of patients with DM2.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Diabetes mellitus tipo 2]]></kwd>
<kwd lng="es"><![CDATA[iSGLT2]]></kwd>
<kwd lng="es"><![CDATA[México]]></kwd>
<kwd lng="en"><![CDATA[Type 2 diabetes mellitus]]></kwd>
<kwd lng="en"><![CDATA[SGLT2i]]></kwd>
<kwd lng="en"><![CDATA[Mexico]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ley]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global aetiology and epidemiology of type 2 diabetes mellitus and its complications]]></article-title>
<source><![CDATA[Nat Rev Endocrinol]]></source>
<year>2018</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>88-98</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>International Diabetes Federation</collab>
<article-title xml:lang=""><![CDATA[IDF Diabetes Atlas]]></article-title>
<source><![CDATA[Eight edition 2017 [internet]. International Diabetes Federation]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>Instituto Nacional de Estadística y Geografía e Instituto Nacional de Salud Pública</collab>
<article-title xml:lang=""><![CDATA[Encuesta Nacional de Nutrición y Salud 2018]]></article-title>
<source><![CDATA[Presentación de resultados [Internet]]]></source>
<year></year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Nacional de Estadística y Geografía e Instituto Nacional de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Basto-Abreu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barrientos-Gutiérrez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas-Martínez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar-Salinas]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[López-Olmedo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[de la Cruz-Góngora]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de diabetes y descontrol glucémico en México:resultados de la Ensanut 2016]]></article-title>
<source><![CDATA[Salud Publica Mex]]></source>
<year>2020</year>
<volume>62</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>50-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cosentino]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Grant]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Aboyans]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ceriello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<collab>ESC Scientific Document Group</collab>
<article-title xml:lang=""><![CDATA[2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2020</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>255-323</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsia]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Grove]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Cefalu]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus]]></article-title>
<source><![CDATA[Curr Opin Endocrinol Diabetes Obes]]></source>
<year>2017</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miranda Fernández-Santos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Egocheaga Cabello]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía práctica de uso de los iSGLT2 en diabetes mellitus tipo 2 [Internet]]]></article-title>
<source><![CDATA[Sociedad Española de Médicos Generales y de Familia]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Seshasai]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Wijesuriya]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sivakumaran]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nethercott]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Preiss]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus:a meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2009</year>
<volume>373</volume>
<page-range>1765-72</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turnbull]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Abraira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Byington]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Chalmers]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Duckworth]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intensive glucose control and macrovascular outcomes in type 2 diabetes]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2009</year>
<volume>52</volume>
<page-range>2288-98</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laiteerapong]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ham]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Moffet]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The legacy effect in type 2 diabetes:impact of early glycemic control on future complications (the Diabetes &amp;Aging Study)]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2019</year>
<volume>42</volume>
<page-range>416-26</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Standards of Medical Care in Diabetes-2020]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2020</year>
<volume>43</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S1-204</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Polidori]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mudaliar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ciaraldi]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Ghosh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vaccaro]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion:results of a randomized, placebo-controlled study]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2013</year>
<volume>36</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2154-61</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Polidori]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Farrell]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ghosh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Natarajan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vaccaro]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacodynamic differences between canagliflozin and dapagliflozin:results of a randomized, double-blind, crossover study]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2015</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>188-97</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Standards of Medical Care in Diabetes-2021]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2021</year>
<volume>44</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S1-S232</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lavalle-González]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Januszewicz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tong]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Qiu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Canovatchel]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy:a randomised trial]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2013</year>
<volume>56</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2582-92</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schernthaner]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenstock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guarisco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yee]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea:a 52-week randomized trial]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2013</year>
<volume>36</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2508-15</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bertoluci]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[VZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk assessment in patients with diabetes]]></article-title>
<source><![CDATA[Diabetol Metab Syndr]]></source>
<year>2017</year>
<volume>9</volume>
<page-range>25</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wanner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lachin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Fitchett]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mattheus]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>137</volume>
<page-range>119-29</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJV]]></given-names>
</name>
<name>
<surname><![CDATA[Cherney]]></surname>
<given-names><![CDATA[DZI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition:the search for the sweet spot in heart failure]]></article-title>
<source><![CDATA[JAMA Cardiol]]></source>
<year>2017</year>
<volume>2</volume>
<page-range>939-40</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sattar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[McLaren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kristensen]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Preiss]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibition and cardiovascular events:why did EMPA-REG Outcomes surprise and what were the likely mechanisms?]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2016</year>
<volume>59</volume>
<page-range>1333-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrannini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mark]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mayoux]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CV protection in the EMPA-REG OUTCOME Trial:a &#8220;Thrifty Substrate&#8221;hypothesis]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2016</year>
<volume>39</volume>
<page-range>1108-14</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baartscheer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schumacher]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Wust]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Fiolet]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Stienen]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Coronel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin decreases myocardial cytoplasmic Na+through inhibition of the cardiac Na+/H+exchanger in rats and rabbits]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2017</year>
<volume>60</volume>
<page-range>568-73</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fedak]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Verma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Weisel]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac remodeling and failure from molecules to man (part II)]]></article-title>
<source><![CDATA[Cardiovasc Pathol]]></source>
<year>2005</year>
<volume>14</volume>
<page-range>49-60</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin?A novel hypothesis]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2018</year>
<volume>20</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1361-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zinman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wanner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lachin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Fitchett]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bluhmki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hantel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>373</volume>
<page-range>2117-28</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[de Zeeuw]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fulcher]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Erondu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canagliflozin and cardiovascular and renal events in type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<page-range>644-57</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[de Zeeuw]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fulcher]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Erondu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<collab>CANVAS Program Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events:Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>137</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>323-34</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Jardine]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bompoint]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Heerspink]]></surname>
<given-names><![CDATA[HJL]]></given-names>
</name>
<name>
<surname><![CDATA[Charytan]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canagliflozin and renal outcomes in type 2 diabetes and nephropathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>380</volume>
<page-range>2295-306</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Raz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bonaca]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Mosenzon]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Cahn]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dapagliflozin and cardiovascular outcomes in type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>380</volume>
<page-range>347-57</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zelniker]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Raz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Im]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Goodrich]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Bonaca]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes:a systematic review and meta-analysis of cardiovascular outcome trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2018</year>
<volume>393</volume>
<numero>10166</numero>
<issue>10166</issue>
<page-range>31-9</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJV]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Kosiborod]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Ponikowski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dapagliflozin in patients with heart failure and reduced ejection fraction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>381</volume>
<page-range>1995-2008</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pocock]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Carson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular and renal outcomes with empagliflozin in heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>383</volume>
<page-range>1413-24</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zannad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Pocock]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitors in patients with heart failure with reduced ejection fraction:a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
<volume>396</volume>
<numero>10254</numero>
<issue>10254</issue>
<page-range>819-29</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cosentino]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Cherney]]></surname>
<given-names><![CDATA[DZI]]></given-names>
</name>
<name>
<surname><![CDATA[Masiukiewicz]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Pratley]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dagogo-Jack]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<collab>VERTIS CV Investigators</collab>
<article-title xml:lang=""><![CDATA[Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease:Results of the VERTIS CV Trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2020</year>
<volume>142</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2205-15</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<collab>KDIGO 2020</collab>
<article-title xml:lang=""><![CDATA[Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2020</year>
<volume>98</volume>
<numero>4S</numero>
<issue>4S</issue>
<page-range>S1-S115</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wanner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Lachin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Fitchett]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[von Eynatten]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mattheus]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin and progression of kidney disease in type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<page-range>323-34</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neuen]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Heerspink]]></surname>
<given-names><![CDATA[HJL]]></given-names>
</name>
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Billot]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2019</year>
<volume>7</volume>
<page-range>845-54</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heerspink]]></surname>
<given-names><![CDATA[HJL]]></given-names>
</name>
<name>
<surname><![CDATA[Stefánsson]]></surname>
<given-names><![CDATA[BV]]></given-names>
</name>
<name>
<surname><![CDATA[Correa-Rotter]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chertow]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hou]]></surname>
<given-names><![CDATA[FF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dapagliflozin in patients with chronic kidney disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>383</volume>
<page-range>1436-46</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Pratley]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dagogo-Jack]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mancuso]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Huyck]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Masiukiewicz]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular outcomes with ertugliflozin in type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>383</volume>
<page-range>1425-35</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[AlKindi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Omary]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Hussain]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Al Hakim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chaaban]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Boobes]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients]]></article-title>
<source><![CDATA[Transplant Proc]]></source>
<year>2020</year>
<volume>52</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>175-8</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahling]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schork]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nadalin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fritsche]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Heyne]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Guthoff]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus]]></article-title>
<source><![CDATA[Kidney Blood Press Res]]></source>
<year>2019</year>
<volume>44</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>984-92</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halden]]></surname>
<given-names><![CDATA[TAS]]></given-names>
</name>
<name>
<surname><![CDATA[Kvitne]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Midtvedt]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rajakumar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Robertsen]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Brox]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2019</year>
<volume>42</volume>
<page-range>1067-74</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajasekeran]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cardella]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schiff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cattral]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cherney]]></surname>
<given-names><![CDATA[DZI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes:A case series]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2017</year>
<volume>40</volume>
<page-range>e75-6</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reyes-García]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Pérez]]></surname>
<given-names><![CDATA[Ó]]></given-names>
</name>
<name>
<surname><![CDATA[Tejera-Pérez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-García]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bellido-Castañeda]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre Casares]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<collab>en representación del Grupo de trabajo de Diabetes-SEEN</collab>
<article-title xml:lang=""><![CDATA[Documento de abordaje integral de la diabetes tipo 2]]></article-title>
<source><![CDATA[Endocrinol Diabetes Nutr]]></source>
<year>2019</year>
<volume>66</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>443-58</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tuttle]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Brosius 3rd]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Cavender]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Fioretto]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fowler]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Heerspink]]></surname>
<given-names><![CDATA[HJL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes:Report of a scientific workshop sponsored by the National Kidney Foundation]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2021</year>
<volume>70</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[JPH]]></given-names>
</name>
<name>
<surname><![CDATA[Barber]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Cuthbertson]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity:Mechanistic possibilities]]></article-title>
<source><![CDATA[Obesity Reviews]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>816-28</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zaccardi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Webb]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Htike]]></surname>
<given-names><![CDATA[ZZ]]></given-names>
</name>
<name>
<surname><![CDATA[Youssef]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Khunti]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus:systematic review and network meta-analysis]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2016</year>
<volume>18</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>783-94</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rigney]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Blak]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Beekman]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Emmas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glycated hemoglobin, body weight and blood pressure in type 2 diabetes patients initiating dapagliflozin treatment in primary care:a retrospective study]]></article-title>
<source><![CDATA[Diabetes Ther]]></source>
<year>2016</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>695-711</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lupsa]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of SGLT2 inhibitors in type 2 diabetes:weighing the risks and benefits]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2018</year>
<volume>61</volume>
<page-range>2118-25</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rådholm]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Foote]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fulcher]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2018</year>
<volume>140</volume>
<page-range>118-28</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogawa]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Sakaguchi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors:possible mechanism and contributing factors]]></article-title>
<source><![CDATA[J Diabetes Investig]]></source>
<year>2016</year>
<volume>7</volume>
<page-range>135-8</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenstock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrannini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Euglycemic diabetic ketoacidosis:a predictable, detectable, and preventable safety concern with SGLT2 inhibitors]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2015</year>
<volume>38</volume>
<page-range>1638-42</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kosiborod]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[CSP]]></given-names>
</name>
<name>
<surname><![CDATA[Kohsaka]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Karasik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<collab>CVD-REAL Investigators and Study Group</collab>
<article-title xml:lang=""><![CDATA[Cardiovascular events associated with SGLT-2 inhibitors vs. other glucose-lowering drugs:The CVD-REAL 2 Study]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2018</year>
<volume>71</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2628-39</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fralick]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schneeweiss]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Patorno]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>376</volume>
<page-range>2300-2</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Douros]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lix]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Fralick]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dell'Aniello]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Ronksley]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis:A multicenter cohort study]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2020</year>
<volume>173</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>417-25</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vardeny]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Vaduganathan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists]]></article-title>
<source><![CDATA[JACC Heart Fail]]></source>
<year>2019</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>169-72</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Buse]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Schuemie]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[DeFalco]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Stang]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus:A real-world meta-analysis of 4 observational databases (OBSERVE-4D)]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2018</year>
<volume>20</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2585-97</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miyashita]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kuno]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Takagi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sugiyama]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ando]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Valentin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors:A meta-analysis of five randomized controlled trials]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2020</year>
<volume>163</volume>
<page-range>108136</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Zhai]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients:a network and cumulative meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2016</year>
<volume>18</volume>
<page-range>1199-206</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Custódio Jr]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Roriz-Filho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cavalcanti]]></surname>
<given-names><![CDATA[CAJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Salles]]></surname>
<given-names><![CDATA[JEN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of SGLT2 Inhibitors in Older Adults:Scientific Evidence and Practical Aspects]]></article-title>
<source><![CDATA[Drugs Aging]]></source>
<year>2020</year>
<volume>37</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>399-409</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cianciolo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De Pascalis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Capelli]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gasperoni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Di Lullo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bellasi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mineral and electrolyte disorders With SGLT2i Therapy]]></article-title>
<source><![CDATA[JBMR Plus]]></source>
<year>2019</year>
<volume>3</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>e10242</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2020</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>70-8</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kristensen]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Henriksen]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Hallas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pottegård]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lund]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2021</year>
<volume>64</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1563-71</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Formiga]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Mañas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Huelgas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Papel de los inhibidores SGLT2 en el paciente anciano con diabetes mellitus;debemos evitar la discriminación por razón de edad]]></article-title>
<source><![CDATA[Rev Esp Geriatr Gerontol]]></source>
<year>2016</year>
<volume>51</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>307-8</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fioretto]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mansfeld]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Ptaszynska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yavin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Johnsson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Parikh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term safety of dapaglifozin in older patients with type 2 diabetes mellitus:a pooled analysis of phase IIb/III studies]]></article-title>
<source><![CDATA[Drugs Aging]]></source>
<year>2016</year>
<volume>33</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>511-22</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinclair]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bode]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vijapurkar]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efcacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus:a pooled analysis]]></article-title>
<source><![CDATA[J Am Geriatr Soc]]></source>
<year>2016</year>
<volume>64</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>543-52</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
